Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.
Liu D, Abbosh P, Keliher D, Reardon B, Miao D, Mouw K, Weiner-Taylor A, Wankowicz S, Han G, Teo MY, Cipolla C, Kim J, Iyer G, Al-Ahmadie H, Dulaimi E, Chen DYT, Alpaugh RK, Hoffman-Censits J, Garraway LA, Getz G, Carter SL, Bellmunt J, Plimack ER, Rosenberg JE, Van Allen EM. Liu D, et al. Among authors: plimack er. Nat Commun. 2017 Dec 19;8(1):2193. doi: 10.1038/s41467-017-02320-7. Nat Commun. 2017. PMID: 29259186 Free PMC article.
Bladder cancer.
Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M; National Comprehensive Cancer Network (NCCN). Clark PE, et al. Among authors: plimack er. J Natl Compr Canc Netw. 2013 Apr 1;11(4):446-75. doi: 10.6004/jnccn.2013.0059. J Natl Compr Canc Netw. 2013. PMID: 23584347
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.
Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ. Choi W, et al. Among authors: plimack er. Cancer Cell. 2014 Feb 10;25(2):152-65. doi: 10.1016/j.ccr.2014.01.009. Cancer Cell. 2014. PMID: 24525232 Free PMC article. Clinical Trial.
PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection.
MacFarlane AW 4th, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, Dulaimi E, Al-Saleem T, Campbell KS. MacFarlane AW 4th, et al. Among authors: plimack er. Cancer Immunol Res. 2014 Apr;2(4):320-31. doi: 10.1158/2326-6066.CIR-13-0133. Epub 2013 Nov 25. Cancer Immunol Res. 2014. PMID: 24764579 Free PMC article.
Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.
Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Plimack ER, et al. J Clin Oncol. 2014 Jun 20;32(18):1895-901. doi: 10.1200/JCO.2013.53.2465. Epub 2014 May 12. J Clin Oncol. 2014. PMID: 24821881 Free PMC article. Clinical Trial.
Micropapillary bladder cancer: current treatment patterns and review of the literature.
Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM. Willis DL, et al. Among authors: plimack er. Urol Oncol. 2014 Aug;32(6):826-32. doi: 10.1016/j.urolonc.2014.01.020. Epub 2014 Jun 13. Urol Oncol. 2014. PMID: 24931270 Free PMC article. Review.
220 results